Caris Life Sciences Inc (CAI) 13F Ownership Report (Q2 2026)

CAI ranks #2515 out of 37696 tracked stocks by institutional interest — one of the most closely watched names in our coverage.

CAI is a disclosed holding of Philippe Laffont (Coatue Management), one of the tracked superinvestors on AlphaSMO — it makes up 0.4% of that fund's own 13F portfolio.

CAI is a top-conviction position for J. H. Whitney Equity Partners VI, LLC — at 100.0% of their entire disclosed 13F portfolio, it's one of their largest single bets, not just a passing allocation.

The largest dollar stake in CAI belongs to FMR LLC, but the position matters far more to J. H. Whitney Equity Partners VI, LLC, who has 100.0% of their own portfolio riding on it — a reminder that the biggest holder by size and the holder with the biggest bet aren't always the same fund.

Zevenbergen Capital Investments LLC has added to its CAI position for two straight quarters, increasing it by $11.1M to reach $22.0M today.

CAI is down 3.8% today, and institutions have been net sellers of $85.9M this quarter — today's price move and the underlying institutional flow are pointing the same direction.

CAI posted net income of $105.1M over the trailing twelve months, and currently trades at a P/E of 48.6.

• Profitable — net income of $105.1M over the trailing twelve months
• Revenue grew 85.4% year over year
• Net income improved year over year, from -$279.0M to $105.1M
• Generated $83.2M in positive operating cash flow
• Current ratio of 7.85x — enough short-term assets to cover short-term liabilities
• Liabilities run 0.95x equity — within a conventional range